Cholesterol Acyltransferase Gene Mutations Have Accelerated Atherogenesis as Assessed by Carotid 3.0-T Magnetic Resonance Imaging Carriers of Lecithin by Duivenvoorden, Raphaël et al.
Journal of the American College of Cardiology Vol. 58, No. 24, 2011
© 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00Atherosclerosis
Cholesterol Acyltransferase Gene Mutations
Have Accelerated Atherogenesis as Assessed
by Carotid 3.0-T Magnetic Resonance Imaging
Carriers of Lecithin
Raphaël Duivenvoorden, MD,* Adriaan G. Holleboom, MD,* Bas van den Bogaard, MD,*
Aart J. Nederveen, PHD,† Eric de Groot, MD, PHD,* Barbara A. Hutten, PHD,‡
Alinda W. Schimmel, BSC,* G. Kees Hovingh, MD, PHD,* John J. P. Kastelein, MD, PHD,*
Jan Albert Kuivenhoven, PHD,* Erik S. G. Stroes, MD, PHD*
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Objectives The aim of this study was to investigate the role of reduced lecithin: cholesterol acyltransferase (LCAT) function
on atherogenesis using 3.0-T carotid magnetic resonance imaging (MRI) and B-mode ultrasound.
Background The role of low high-density lipoprotein cholesterol as a causal factor in atherogenesis has recently been ques-
tioned. LCAT plays a key role in high-density lipoprotein cholesterol metabolism.
Methods Carotid 3.0-T MRI and B-mode ultrasound measurements were performed in 40 carriers of LCAT gene mutations
and 40 controls, matched for age. Patients with cardiovascular disease were excluded.
Results Carriers had 31% lower LCAT activity levels and 38% decreased high-density lipoprotein cholesterol levels (both
p  0.001 vs. controls). Carriers presented with a 10% higher normalized wall index (0.34  0.07 vs. 0.31 
0.04, p  0.002), a 22% higher mean wall area (17.3  8.5 mm2 vs. 14.2  4.1 mm2, p  0.01), and a 22%
higher total wall volume (1,039  508 mm3 vs. 851  247 mm3, p  0.01 vs. controls) as measured by MRI.
The prevalence (20 vs. 5, p  0.002) and the total volume (102 mm3 vs. 3 mm3) of atherosclerotic plaque compo-
nents on MRI relating to lipid-rich tissue or calcification were also higher in carriers than in controls. All differences
retained significance after adjustment for age, sex, blood pressure, low-density lipoprotein cholesterol, body mass
index, smoking, and family history of cardiovascular disease. Common carotid intima-media thickness measured with
ultrasound was increased in carriers by 12.5% (0.72  0.33 mm vs. 0.64  0.15 mm, p  0.14).
Conclusions Carriers of LCAT gene mutations exhibit increased carotid atherosclerosis, indicating an increased risk of cardiovascular
disease. The present findings imply that increasing LCAT activity may be an attractive target in cardiovascular prevention
strategies. (J Am Coll Cardiol 2011;58:2481–7) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.092A low plasma high-density lipoprotein cholesterol (HDL-C)
level is among the strongest risk factors for cardiovascular
disease (CVD) (1). One of the mechanisms by which
high-density lipoprotein (HDL) is considered to convey
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2010, accepted November 8, 2010.atheroprotection is the removal of excess cholesterol from
lipid-laden foam cells in the artery wall and transport it to
the liver for fecal excretion, a process referred to as reverse
cholesterol transport (2). A crucial enzyme in HDL
See page 2488
metabolism is lecithin:cholesterol acyl transferase (LCAT)
(3,4). This plasma enzyme, produced in the liver and small
intestine, is predominantly associated with HDL and es-
terifies free cholesterol using apolipoprotein A-I as a cofac-
tor (3). Homozygotes for deleterious mutations in the
LCAT gene are characterized by nearly complete HDL-C
deficiency (90% reduction), whereas heterozygotes have
profoundly reduced HDL-C levels (40% reduction) com-
pared with normal (5–8).
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Atherosclerosis in LCAT Mutation Carriers December 6, 2011:2481–7To date, the relationship be-
tween LCAT and atherosclerosis
has been a matter of debate. An-
imal studies have not been able
to provide a clear answer because
both LCAT knockout models
and LCAT overexpression mod-
els yielded mixed results with
respect to atherogenesis, as re-
cently reviewed (9). Human
studies have also been conflict-
ing. Hovingh et al. (10) reported
that carriers of LCAT gene mu-
tations have increased carotid
intima-media thickness (IMT)
(as quantified by B-mode ultra-
sound imaging) compared with
family controls. In contrast, Cala-
bresi et al. (11) recently reported
that carotid IMT was decreased in
carriers while using the same ultra-
sound methodology. These con-
tradictory outcomes are difficult to
interpret and may result from pop-
ulation differences. Furthermore, a
limitation of previous studies is
that carotid ultrasound lacks statis-
tical power to reliably measure ar-
erial wall thickness in small population studies because ultra-
ound provides 2-dimensional longitudinal images, whereas
therosclerosis is a 3-dimensional eccentric developing disease.
agnetic resonance imaging (MRI) might overcome these
maging limitations because it enables transverse 3-dimensional
maging of atherosclerosis at high resolution with excellent
nterscan reproducibility (12).
In the present study, we set out to assess the relationship
etween LCAT and carotid atherosclerosis using carotid
.0-T MRI in parallel with carotid B-mode ultrasound
maging, comparing carriers of LCAT mutations and con-
rols. We hypothesized that carriers of LCAT gene muta-
ions had increased atherosclerosis compared with controls.
ethods
tudy design. In this study, the extent of carotid athero-
clerosis in subjects with LCAT gene mutations and age-
atched controls was compared. The study was conducted
t the Academic Medical Center in Amsterdam, the Neth-
rlands from October 2008 to October 2009. The study
rotocol was reviewed and approved by the institutional
eview board, and all subjects gave written informed
onsent.
The 3 probands of the families in which we identified
CAT mutations had presented to the ophthalmologists
ith corneal clouding, after which they were referred to our
Abbreviations
and Acronyms
BMI  body mass index
CCIMT  common carotid
intima-media thickness
CVD  cardiovascular
disease
FED  fish eye disease
FLD  familial LCAT
deficiency
HDL  high-density
lipoprotein
HDL-C  high-density
lipoprotein cholesterol
IMT  intima-media
thickness
LCAT  lecithin:cholesterol
acyltransferase
LDL-C  low-density
lipoprotein cholesterol
MRI  magnetic resonance
imaging
MWA  mean wall area
NWI  normalized wall
index
PC  plaque componentipid clinic. Subsequently, we performed genetic testing in aheir family members to identify subjects with LCAT
utations. Carriers of molecularly diagnosed LCAT muta-
ions (DNA and LCAT activity) were enrolled in this study,
rrespective of their age and sex. Probands with CVD and
heir family members were excluded. For the control group,
amily members of the included carriers were asked to
articipate in the study and were first-, second-, or third-
egree family members or spouses. They were included if
hey could be matched for age with a carrier. Because
nsufficient numbers of unaffected family controls (N  19)
olunteered, we matched the control group with unrelated
ontrols (N  21) recruited by advertisement. Exclusion
riteria for both carriers and controls were a history of CVD,
revious carotid surgery, or any contraindication to MRI.
uestionnaire, biometric, and biochemical measurements.
he presence of cardiovascular risk factors, use of medica-
ion, and family history of CVD were assessed by a
uestionnaire. Brachial artery blood pressures were mea-
ured using an oscillometric blood pressure device (Omron
05IT, Hoofddorp, the Netherlands). The presence of
ypertension was defined as a systolic blood pressure 140
m Hg, a diastolic blood pressure 90 mm Hg or the use
f antihypertensive medication. Weight and length were
easured to calculate body mass index (BMI).
Ethylenediamine tetraacetic acid plasma obtained through
enous blood samples were obtained after overnight fasting
nd stored using standardized protocols. Plasma total cho-
esterol, HDL-C and triglyceride levels were analyzed using
commercially available enzymatic method (colorimetric
ssay with the CHOD-PAP and GPO-PAP kits) (West-
urg) on a Cobas Mira autoanalyzer (Roche, Mannheim,
witzerland). Low-density lipoprotein cholesterol (LDL-C) lev-
ls were calculated using the Friedewald equation. LCAT
ctivity was measured using a proteoliposome substrate as
reviously described (10).
arotid MRI. Scans were performed with a 3.0-T Philips
Best, the Netherlands) whole-body scanner using a single-
lement microcoil with a diameter of 5 cm. Cardiac gated
xial T1-weighted turbo spin echo image stacks were
cquired at end-diastole using a double inversion recovery
reparation and active fat suppression. Sequence parameters
ere slice thickness of 3 mm, imaging matrix size of 240,
eld of view of 60  60 mm, noninterpolated pixel size of
.25  0.25 mm, echo time of 9 ms, recovery time
ccording to the subjects’ heart rate (approximately 900 ms),
cho train length of 7, echo train duration of 63 ms. To
ocalize the left and right common carotid artery and carotid
ifurcation, axial magnetic resonance angiography images
ere acquired using a time-of-flight sequence. These im-
ges together with projection images were used for posi-
ioning the scan planes perpendicular to the vessel at a
redefined distance distal to the flow divider. Ten slices
ere scanned of the distal 3.0 cm of the left and right
ommon carotid artery. The slices were located from 9 mm
o 39 mm proximal to the carotid flow divider. Each carotid
rtery was scanned individually. A total of 20 images were
o
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December 6, 2011:2481–7 Atherosclerosis in LCAT Mutation Carriersobtained per scan. All images were saved in DICOM
format. Standardized equipment and protocols were used
for image storage and data management. The imaging
protocol and image analysis were described previously
(12,13).
Quantitative image analysis was performed using semi-
automated measurement software (VesselMass, Leiden
University Medical Center, Leiden, the Netherlands) (14).
One reader, blinded to group and any other data of the
participants, analyzed all the images. The mean wall area
(MWA), lumen area, outer wall area, and total wall volume
were measured. The normalized wall index (NWI) was
calculated as: NWI  MWA/outer wall area. Also, the
prevalence of plaque components (PCs) and total PC
volume (mm3) were assessed. PC was defined as a T1-
weighted image on which an area of decreased signal
intensity within the artery wall was identified. Previous
studies showed that areas in the artery wall with decreased
signal intensity on T1-weighted images represent either
lipid-rich tissue or calcification (15). The prevalence of PC
was reported as the total number of images per group that
showed PC. Also the volume of PCs was quantified and
reported as the sum of all PC volumes of all subjects per
group.
Carotid ultrasound imaging. Carotid B-mode ultrasound
scans of the left and right common, bulb, and internal
carotid arterial far walls were assessed with a single-angle
imaging protocol, with the transducer axis parallel to a
virtual ear-to-ear line, according to our standardized proto-
col as previously described (16). One experienced and
certified sonographer performed all scans, and 1 reader
analyzed all the images, blinded to group and any other data
of the participants. Images were analyzed quantitatively
offline by 1 certified image analyzer using validated software
(eTrack, Academic Medical Center, Amsterdam, the Neth-
erlands). The primary ultrasound parameter was defined as
the mean common carotid intima-media thickness
(CCIMT) (defined as the average far wall IMT of the left
and right distal 1 cm of the common carotid artery). A
secondary ultrasound endpoint entailed the mean carotid
IMT, defined as the average far wall IMT of the left and
right common, bulb, and internal carotid arterial wall
segments.
Outcome parameters. The NWI was the primary outcome
parameter of the study. A priori, based on previous study
data and assuming a 2-sided  of 0.05 and  of 0.2 (power
f 80%), we calculated that a sample of at least 38 subjects
er group was required to detect a 0.02 difference in the
WI between groups. Secondary MRI outcome parameters
ere MWA (square millimeters), and total wall volume
cubic millimeters). Secondary ultrasound outcome param-
ters were CCIMT (millimeters) and IMT (millimeters).
xploratory endpoints were PC prevalence (number) and
otal PC volume (cubic millimeters) assessed by MRI.
tatistical analysis. Continuous variables are expressed as
ean  SD, unless otherwise specified. Differences in aemographic, biometric, and biochemical parameters be-
ween carriers of LCAT gene mutations and controls were
ssessed using an unpaired Student t test or chi-square test,
here appropriate. Differences in carotid imaging parame-
ers between carriers of LCAT gene mutations and controls were
ssessed using an unpaired Student t tests, unless otherwise
pecified. In addition, a multivariate model was used with
eneralized estimating equations in the SAS procedure
ENMOD (SAS Institute Inc., Cary, North Carolina) to
ccount for age, sex, hypertension (systolic blood pressure
140 mm Hg, diastolic blood pressure90 mm Hg, or the
se of antihypertensive medication), LDL-C, BMI, smok-
ng, family history of CVD, and correlations within families
ue to clustering of genetic and/or environmental factors.
o compare the agreement between MRI and ultrasound
cans within patients, we assessed the infraclass correlation
oefficients (r) and mean paired difference between MWT
MRI) and CCIMT (ultrasound). Statistical analyses were
one using SPSS version 16.0 (SPSS Inc., Chicago, Illinois)
nd SAS version 9.0 (SAS Institute Inc., Cary, North
arolina).
esults
opulation characteristics. We studied 40 carriers of
CAT gene mutations (from 14 families of Dutch descent)
nd 40 age-matched controls, 19 of whom were family
embers and 21 were unrelated individuals. Mutations in
he LCAT gene can either cause loss of enzymatic activity
n only HDL ( activity) or loss of activity on both HDL
nd LDL ( and  activity, respectively) (8). Clinically, this
ranslates into 2 different autonomic recessive disorders: fish
ye disease (FED) (only loss of  activity) and familial
LCAT deficiency (FLD) (loss of both  and  activity)
5–7). Whereas both FED and FLD patients present with
ow HDL-C, only FLD patients also exhibit lower LDL-C
evels (5–7). Of the carriers, 38 had 1 mutant LCAT allele,
hereas 2 were homozygotic for a defect that underlay
linically manifest FED (corneal pacification). Thirty-three
f the 40 carriers had a mutation that is known to cause
ED when present on both alleles. Four individuals were
eterozygotes for a mutation that is known to cause FLD
hen present on both alleles. Finally, 3 subjects carried
CAT gene point mutations, but it is unknown whether
hey cause FED or FLD when present on both alleles (no
omozygous patients described). Table 1 summarizes the
emographic, lifestyle, and clinical characteristics of carriers
nd controls. Age, sex, smoking, alcohol use, blood pressure,
iabetes, fasting glucose level, fasting insulin level, Homeo-
tatic Model Assessment index, hypertension, and the Fra-
ingham risk score were similar. BMI tended to be higher in
he carriers, but this was not statistically significant. In addi-
ion, more lipid-lowering medication, especially statins, and
scal (calcium carbsalate) were prescribed in the carriers.
Table 1 also gives the results of lipid, (apo)lipoprotein,nd LCAT activity measurements. Carriers had 8% lower
static M
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Atherosclerosis in LCAT Mutation Carriers December 6, 2011:2481–7total cholesterol (p  0.04), which could be attributed to a
38% reduction of HDL-C levels (p  0.001) with similar
LDL-C levels in both groups. Plasma triglyceride levels
were 27% higher in carriers compared with controls (p 
0.06). Apolipoprotein B levels were identical, whereas
carriers had 20% lower apolipoprotein A-I levels (p 
0.001). LCAT activity levels were 31% lower in carriers
compared with controls (p  0.001).
Carotid MRI and ultrasound. Mean  SD of MRI and
ultrasound parameters are shown in Table 2. The NWI, the
primary endpoint of this study, was significantly increased in
carriers compared with controls (p 0.02), as shown in Figure 1.
Statistical corrections for differences in age, sex, hyperten-
sion, LDL-C, BMI, smoking, family history of CVD, and
clustering of genetic and/or environmental factors in fami-
lies rendered stronger statistical significance (p  0.002).
The NWI in unaffected family controls was similar to that
of unrelated controls (0.30  0.04 vs. 0.31  0.05, p 
0.57). We also assessed differences in plaque composition. The
prevalence of PC related to lipid-rich tissue or calcification (PC
Characteristics of Carriers of LCAT Gene MutatTable 1 Characteristics of Carriers of LCAT
Carriers of LCA
(n 
Characteristics
Age, yrs 42.4
Male 27
Body mass index, kg/m2 25.7
Smokers 6
Alcohol use, U/week 5.8
Medication use
Statin 11
Ezetimibe 3
Niacin 3
Fibrate 1
Aspirin 3
Blood pressure, mm Hg
Systolic 131
Diastolic 78
Hypertension 10
Glucose metabolism
Fasting glucose, mmol/l 5.2
Fasting insulin, mU/l 5.1
HOMA index 1.2
Diabetes 0
Lipid metabolism
Total cholesterol, mg/dl 175.4
LDL-C, mg/dl 126.5
HDL-C, mg/dl 34.1
Triglycerides, mg/dl 104.4 (8
Apolipoprotein B, mg/dl 103.1
Apolipoprotein A-I, mg/dl 119.9
LCAT activity, nmol · ml1 · h1 9.24
Values are mean  SD or n (%). Male sex, smokers, medication use, h
Student t test. Hypertension was defined as systolic blood pressu
antihypertensive medication. For triglycerides, we report the median a
HDL-C  high-density lipoprotein cholesterol; HOMA index  Homeo
LDL-C  low-density lipoprotein cholesterol.prevalence) was 25% higher (20 vs. 6) and the total PC volumewas 34 times larger in carriers than in controls. Ultrasound
CCIMT, and IMT were increased in carriers, but these
differences did not reach statistical significance. There was
excellent agreement between MWT (MRI) and CCIMT
(ultrasound), with an intraclass correlation coefficient of 0.91
(95% confidence interval: 0.86 to 0.94, p 0.001), and a mean
paired difference of 0.01  0.11 mm.
Discussion
The present study shows that carriers of LCAT gene
mutations exhibit increased carotid artery wall thickening as
assessed by 3.0-T MRI compared with age-matched con-
trols. This finding has clinical relevance because carotid
artery wall thickening is associated with an increased risk of
cardiovascular events (17,18). Although previous carotid
ultrasound studies were unable to achieve consensus on the
impact of LCAT gene mutations on carotid atherosclerosis
(10,11), the current MRI data lend support to the concept
that decreased LCAT function, as a result of LCAT gene
nd ControlsMutations and Controls
Mutations Controls
(n  40) p Value
.0 42.3 14.1 0.97
23 (58) 0.36
24.5 3.5 0.17
6 (15) 1.0
7.8 7.9 0.22
1 (3) 0.05
0 (0) 0.08
0 (0) 0.08
0 (0) 0.31
0 (0) 0.08
128 13 0.29
76 9 0
6 (15) 0.26
5.3 0.9 0.49
5.2 7.3 0.94
1.5 2.4 0.67
1 (3) 0.31
0.04
.1 190.8 41.6
.4 123.6 31.4 0.69
.9 54.4 16.2 0.001
6.2) 82.3 (55.3–126.1) 0.06
.6 100.7 23.8 0.68
.9 150.6 25.7 0.001
5 12.85 2.92 0.001
sion, diabetes: p value for chi-square test; for other parameters: p for
0 mm Hg, diastolic blood pressure 90 mm Hg, or the use of
rquartile range; p value for t test after log-transformation.
odel Assessment index; LCAT  lecithin:cholesterol acyltransferase;ions aGene
T Gene
40)
 13
(68)
 4.0
(15)
 5.5
(28)
(8)
(8)
(3)
(0)
 13
 9
(25)
 0.8
 8.9
 2.1
(0)
 44
 33
 13
0.8–14
 25
 31
 2.9
yperten
re 14
nd intemutations, is associated with accelerated atherogenesis.
se; MW
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December 6, 2011:2481–7 Atherosclerosis in LCAT Mutation CarriersThe aim of our study was to test the hypothesis that
decreased LCAT function is associated with accelerated
atherogenesis. To this end, we investigated 2 parameters of
atherosclerosis with MRI: arterial wall thickening and the
presence of PC. First, the data show that the carriers of
LCAT gene mutations have thickened carotid artery walls
compared with controls with significant increases in NWI,
MWA, and total wall volume. These differences remained
statistically significant after adjustments for age, sex, hyper-
tension, LDL-C, BMI, smoking, family history of CVD,
and clustering of genetic and/or environmental factors in
families. Second, carriers presented with a 32% increased
Carotid 3.-T Magnetic Resonance Imaging and BUlt asound Param ers for C rriers of LCAT GenTable 2 Carotid 3.-T Magnetic Reso ance ImUltrasound Parameters for Carriers
Carriers of LCAT Gen
(n  40)
3.0-T MRI
NWI 0.34 (0.07
MWA, mm2 17.3 (8.5)
TWV, mm3 1,039 (508
LA, mm2 32.5 (6.7)
Plaque composition analysis
PC presence 20 (2.5)
Total PC volume, mm3 102
B-mode ultrasound
CCIMT, mm 0.72 (0.33
IMT, mm 0.75 (0.36
Values are n (%) or n. *p Value for the unadjusted model. †p Value fo
low-density lipoprotein cholesterol, smoking status, and family histor
environmental factors in families. ‡p Value for chi-square test.
CCIMTmean common carotid intima media thickness; IMT ave
arteries; LA  lumen area; LCAT  lecithin:cholesterol acyltransfera
component; TWV  total wall volume.
Figure 1
Comparison of Carotid Atherosclerosis in
Carriers of Lecithin:Cholesterol Acyltransferase
Gene Mutations and Controls
The mean and 95% confidence intervals for a normalized wall index measured
by 3.0-T magnetic resonance imaging are shown for each group. The p value is
adjusted for age, sex, body mass index, hypertension, low-density lipoprotein
cholesterol, smoking status, family history of cardiovascular disease, and clus-
tering of genetic and/or environmental factors in families.prevalence of PC and 16.5 times larger total PC volume
compared with controls. These are features of carotid artery
plaques that have been associated with increased cardiovas-
cular event rates (17,18). Combined, these findings point to
accelerated atherogenesis in individuals with reduced
LCAT function.
We also assessed atherogenesis by means of carotid
ultrasound IMT measurements. Whereas IMT parameters
tended toward an increase in carriers, the differences did not
reach statistical significance. The latter most likely pertains
to the lack of power, as attested to by the significant MRI
findings. In fact, we previously showed that the measure-
ment variability of carotid 3.0-T MRI is less compared with
that of ultrasound IMT (12).
Various studies have attempted to unravel the relation-
ship between LCAT function and CVD in humans. Recent
genome-wide association studies revealed that LCAT cor-
relates with HDL-C levels, but not to CVD risk (19,20).
The prevalence of single nucleotide polymorphisms in the
population, however, is low, and it is unknown whether
these single nucleotide polymorphisms actually affect
LCAT function. Moreover, total variation in HDL-C
explained by LCAT single nucleotide polymorphisms was
very small. Therefore, genome-wide association studies may
not be the most sensitive technique to detect a relationship
between LCAT and CVD. In cross-sectional studies in
patients with either angiographically documented coronary
artery disease or acute myocardial infarction, both decreased
and increased LCAT activity have been observed (21–23).
A recent prospective nested case-control study examined
LCAT concentration in 2,785 healthy subjects with a
follow-up of 6 years (24). In this study, LCAT levels did not
differ between cases and controls. However, because the
variation of LCAT concentration in this population was
etations and Controlsg and B-mode
AT Gene Mutations and Controls
tions Controls
(n  40) p Value*
Adjusted
p Value†
0.31 (0.04) 0.02 0.002
14.2 (4.1) 0.02 0.01
851 (247) 0.02 0.01
31.3 (5.1) 0.32 0.72
5 (0.6) 0.002‡
3
0.64 (0.15) 0.19 0.14
0.69 (0.23) 0.39 0.53
variate model adjusting for age, sex, body mass index, hypertension,
diovascular disease and accounting for clustering of genetic and/or
an intima media thickness of the common, bulb, and internal carotid
A  mean wall area; NWI  normalized wall index; PC  plaque-mode Muagin
of LC
e Muta
)
)
)
)
r multi
y of car
rage mesmall, a potential contribution of LCAT to CVD risk may
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Atherosclerosis in LCAT Mutation Carriers December 6, 2011:2481–7have been overcome by other risk factors, such as diabetes
mellitus, smoking, blood pressure, BMI, and LDL-C.
Two previous imaging studies have addressed the rela-
tionship between LCAT and atherosclerosis in carriers of
LCAT gene mutations using carotid IMT. Hovingh et al.
(10) showed that carotid IMT was significantly increased in
the carriers, whereas Calabresi et al. (11) showed the
opposite, with carotid IMT being significantly decreased in
carriers. This apparent discrepancy may be explained by
differences in the populations. The carriers in the current
study and in the Hovingh et al. (10) study predominantly
had a different type of LCAT mutation than those in the
study of Calabresi et al. (11). In both the Hovingh et al. (10)
study and the present study, the vast majority of carriers of
LCAT gene mutations exhibited a loss of  activity (LCAT
activity on HDL), whereas Calabresi et al. (11) predomi-
nantly investigated individuals with loss of function muta-
tions of  and  activity (LCAT activity on HDL and
DL). Accordingly, LDL-C levels in the current study
ere 23% higher compared with those in the Calabresi et al.
11) study (127 mg/dl vs. 103 mg/dl, respectively). In fact,
he average LDL-C of the patients studied by Calabresi et
l. (11) was in line with the National Cholesterol Education
rogram ATPIII guidelines. In fact, the absence of the
rimary trigger of atherosclerosis, that is, increased LDL-C,
n the Calabresi et al. (11) study may be an important
xplanation why they did not observe increased atherogen-
sis in their familial LCAT-deficient patients.
To date, it has been unclear how to monitor and treat
arriers of LCAT gene mutations. Whereas, ideally, a
rospective, randomized, controlled trial is required to settle
his issue, this type of evidence is unlikely to become
vailable given the rareness of the disease. Considering the
resent data combined with the fact that decreased levels of
DL-C are strongly associated with CVD risk, we propose
lose monitoring and treatment of CVD risk factors in both
eterozygous and homozygous patients with LCAT gene
utations. The current study results support a distinct role
f LCAT in atherogenesis. Whether this effect relates to the
ffects on HDL-C or to, for example, the anti-inflammatory
roperties (25,26) attributed to LCAT cannot be deter-
ined by the current study.
tudy limitations. A limitation inherent to this type of
mall cohort study is referral bias of the examined individ-
als. Carriers and family controls were recruited using the
ame method, whereas unrelated controls were recruited by
dvertisement. Nonetheless, related and unrelated controls
ere similar in terms of the NWI, so it is unlikely that
ifferences in recruitment methods introduced bias. Fur-
hermore, we attempted to minimize this effect by excluding
atients with pre-existing CVD and included only carriers
dentified in families in which the probands were asymp-
omatic for CVD. These probands presented either with
arked corneal clouding or low HDL-C levels identifiedhrough (random) screening for CVD risk factors.onclusions
he present study shows that carriers of LCAT gene
utations have increased carotid atherosclerosis com-
ared with controls. Our data have 2 clinical implica-
ions. First, because carriers of LCAT gene mutations
ave experienced lifelong exposure to marked dyslipide-
ia and the current data suggest that they are at
ncreased risk of the development of atherosclerosis, close
onitoring and treatment of CVD risk factors is advo-
ated. Second, based on these data, it is tempting to
peculate that increasing LCAT activity is an interesting
arget to reduce cardiovascular risk (27,28).
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